Abstract
Despite multiple advances in prostate cancer therapy, treatment options for castration resistant disease are very limited. While data from recent studies are encouraging, there is no drug that has significantly improved results of standard chemotherapy. Some of the most consistent results are provided by antiangiogenic agents, showing high response rates and manageable toxicity. We describe some of the main therapeutic angiogenesis inhibitors in metastatic castration resistant prostate cancer. These agents include vascular endothelial growth factor inhibitors, tyrosine kinase inhibitors, antiangiogenic and inmunomodulatory agents and endothelin receptor antagonists.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Atrasentan
-
Benzenesulfonates / therapeutic use
-
Castration / methods
-
Drug Resistance, Neoplasm*
-
Endothelin Receptor Antagonists
-
Endothelins / antagonists & inhibitors*
-
Humans
-
Indoles / therapeutic use
-
Lenalidomide
-
Male
-
Niacinamide / analogs & derivatives
-
Phenylurea Compounds
-
Prostatic Neoplasms / blood supply*
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / metabolism
-
Prostatic Neoplasms / pathology
-
Protein Kinase Inhibitors / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Pyridines / therapeutic use
-
Pyrroles / therapeutic use
-
Pyrrolidines / therapeutic use
-
Quinazolines / therapeutic use
-
Sorafenib
-
Sunitinib
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents, Hormonal
-
Benzenesulfonates
-
Endothelin Receptor Antagonists
-
Endothelins
-
Indoles
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Pyridines
-
Pyrroles
-
Pyrrolidines
-
Quinazolines
-
Vascular Endothelial Growth Factor A
-
ZD4054
-
Niacinamide
-
Thalidomide
-
Sorafenib
-
Protein-Tyrosine Kinases
-
Lenalidomide
-
cediranib
-
Atrasentan
-
Sunitinib